SCHEMBL43565

SCHEMBL43565

O=C1c2cccc3cccc(c23)C(=O)N1O.[NaH]

nearest known ligand 0.96

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC1 P07992 2/20 0.96
FEN1 P39748 2/20 0.96
ERCC4 Q92889 2/20 0.96
ALDH1A1 P00352 9/20 0.60
KDM4E B2RXH2 6/20 0.60
HPGD P15428 4/20 0.60
KMT2A Q03164 3/20 0.60
HSD17B10 Q99714 3/20 0.60
MEN1 O00255 2/20 0.60
HEXA P06865 3/20 0.56
HEXB P07686 3/20 0.56
CYP1B1 Q16678 1/20 0.55
MAPT P10636 3/20 0.55
CYP1A2 P05177 2/20 0.55
POLB P06746 2/20 0.55
AKR1B1 P15121 1/20 0.55
ALOX15 P16050 1/20 0.55
TSHR P16473 1/20 0.55
ALOX12 P18054 1/20 0.55
TDP1 Q9NUW8 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL132760 0.98 ERCC1 (1.00) ERCC1FEN1ERCC4ALDH1A1KDM4E
SCHEMBL29410043 0.98 ERCC1 (1.00) ERCC1FEN1ERCC4ALDH1A1KDM4E
SCHEMBL27984890 0.96 ERCC1 (0.96) ERCC1FEN1ERCC4ALDH1A1KDM4E
SCHEMBL4888025 0.96 ERCC1 (0.96) ERCC1FEN1ERCC4ALDH1A1KDM4E
Methane SCHEMBL20512282 0.96 ERCC1 (0.96) ERCC1FEN1ERCC4ALDH1A1KDM4E
SCHEMBL65320 0.87 ERCC1 (0.79) ERCC1FEN1ERCC4ALDH1A1KDM4E
Trifluoromethanesulfonic Acid SCHEMBL51719 0.82 ERCC1 (0.71) ERCC1FEN1ERCC4ALDH1A1KDM4E
SCHEMBL7706742 0.81 ERCC1 (0.70) ERCC1FEN1ERCC4ALDH1A1KDM4E
SCHEMBL7706718 0.81 ERCC1 (0.70) ERCC1FEN1ERCC4ALDH1A1KDM4E
SCHEMBL7703367 0.81 ERCC1 (0.70) ERCC1FEN1ERCC4ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11213804-B2 Dehydrogenation catalysts and methods of making and using the same EXXONMOBIL CHEMICAL PATENTS INC. (US) 2022-01-04 US disclosed
EP-3327003-B1 PROCESS FOR CONCENTRATING A MIXTURE CONTAINING ORGANIC HYDROPEROXIDE EXXONMOBIL CHEMICAL PATENTS INC (US) 2020-09-16 EP disclosed
CN-106716252-B Photosensitive resin composition, cured film and method for producing same, liquid crystal display device, organic electroluminescence display device, and touch panel 富士胶片株式会社 2020-01-07 CN disclosed
CN-106687865-B TFT substrate, organic EL display device, and method for manufacturing liquid crystal display device 富士胶片株式会社 2020-01-03 CN disclosed
EP-3180304-B1 PROCESS FOR PRODUCING CYCLOHEXANONE EXXONMOBIL CHEMICAL PATENTS INC (US) 2019-10-30 EP disclosed
US-20190283002-A1 Dehydrogenation Catalysts and Methods of Making and Using the Same EXXONMOBIL CHEMICAL PATENTS INC. 2019-09-19 US disclosed
EP-3013779-B1 PROCESS FOR PRODUCING PHENOL AND/OR CYCLOHEXANONE EXXONMOBIL CHEMICAL PATENTS INC (US) 2019-07-31 EP disclosed
EP-3013795-B1 PROCESS FOR CONCENTRATING A MIXTURE CONTAINING ORGANIC HYDROPEROXIDE EXXONMOBIL CHEMICAL PATENTS INC (US) 2019-07-24 EP disclosed
US-10351506-B2 Purified plasticizers, production and use EXXONMOBIL CHEMICAL PATENTS INC. (US) 2019-07-16 US disclosed
US-20190176131-A1 Methods of Making Supported Mixed Metal Dehydrogenation Catalysts EXXONMOBIL CHEMICAL PATENTS INC. 2019-06-13 US disclosed
US-20020198135-A1 Compositions for release of radiosensitizers, and methods of making and using the same JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE 2002-12-26 US disclosed
WO-2002030472-A2 COMPOSITIONS FOR RELEASE OF RADIOSENSITIZERS, AND METHODS OF MAKING AND USING THE SAME GUILFORD PHARMACEUTICALS, INC. (US) 2002-04-18 WO disclosed
US-6358975-B1 ADMINISTERING 3,4-DIHYDRO-5-(4-(1-PIPERIDINYL)-BUTOX)-1 (2H)-ISOQUINOLINONE, A SELECTIVE INHIBITOR OF POLY(ADP-RIBOSE) POLYMERASE FOR PROPHYLAXIS OF NEURAL TISSUE DAMAGE RESULTING FROM ISCHEMIA AND REPERFUSION INJURY OR NEURODEGENERATIVE JOHNS HOPKINS UNIVERSITY 2002-03-19 US disclosed
US-6348475-B1 POLYMERASE INHIBITOR GUILFORD PHARMACEUTICALS INC. 2002-02-19 US disclosed
US-20020019417-A1 Methods, compounds and compositions for treating gout EISAI INC. 2002-02-14 US disclosed
WO-2001091796-A2 METHODS, COMPOUNDS AND COMPOSITIONS FOR TREATING GOUT GUILFORD PHARMACEUTICALS INC. (US) 2001-12-06 WO disclosed
US-6242245-B1 DELIGNIFICATION BY ADDING SUSPENSION OF LACCASE, OXIDANT, MEDIATOR SUCH AS VIOLURIC ACID, AND XYLANASE TO AQUEOUS SUSPENSION OF LIGNIN MATERIAL AND MIXING; MEDIATOR DOES NOT DEACTIVATE ENZYME Consortium für elektrochemische Industrie GmbH (DE) 2001-06-05 US disclosed
US-6187170-B1 SYSTEM FOR THE ELECTROCHEMICAL CLEAVAGE OF COMPOUNDS WHICH INCLUDES A MEDIATOR AND AT LEAST TWO ELECTRODES FOR THE ELECTROCHEMICAL ACTIVATION OF THE MEDIATOR Consortium für elektrochemische Industrie GmbH (DE) 2001-02-13 US disclosed
US-6160128-A Tritioacetylating reagents and processes for preparation thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-12-12 US disclosed
WO-1999008680-A1 METHOD OF USING SELECTIVE PARP INHIBITORS TO PREVENT OR TREAT NEUROTOXICITY THE JOHNS HOPKINS UNIVERSITY (US) 1999-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11213804-B2 Dehydrogenation catalysts and methods of making and using the same IDH2, ADH4, IDH1 ERCC1 1492/4885FEN1 448/4885ERCC4 1146/4885
US-10351506-B2 Purified plasticizers, production and use ALKBH3, FTO, ALK ERCC1 625/4885FEN1 494/4885ERCC4 1069/4885
US-20190176131-A1 Methods of Making Supported Mixed Metal Dehydrogenation Catalysts SOD1, DNMT1, CA1 ERCC1 1224/4885FEN1 389/4885ERCC4 1144/4885
US-20020198135-A1 Compositions for release of radiosensitizers, and methods of making and using the same XRCC6, MRE11, RAD51 ERCC1 6/4885FEN1 263/4885ERCC4 13/4885
US-20020019417-A1 Methods, compounds and compositions for treating gout PARP2, PARP1, PARP3 ERCC1 139/4885FEN1 201/4885ERCC4 102/4885
US-20190283002-A1 Dehydrogenation Catalysts and Methods of Making and Using the Same IDH2, ADH4, IDH1 ERCC1 1492/4885FEN1 448/4885ERCC4 1146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.